Skip to content
Screener

Operating Income at other companies

Amgen logo
AmgenAMGN
$3.51B+32.3%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$1.29B+19.8%
Gilead Sciences logo
Gilead SciencesGILD
-$10.39B-520%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$126.27M-18.3%
Biohaven logo
BiohavenBHVN
-$130.43M+41.1%
Assembly Biosciences logo
Assembly BiosciencesASMB
-$11.37M-14.4%

Other financials

Income statement

See full
Revenue$238.9M+19,583%
Gross profit$238.9M+19,763%
Net income$80.1M+172%
EPS (diluted)$0.47+159%

Balance sheet

See full
Cash & equivalents$287.6M-6.1%
Total debt$93.3M-8.8%
Total equity$982.5M+3.7%
Total assets$1.2B+1.9%

Cash flow

See full
Operating cash flow-$132.4M-69.5%
CapEx$32.0K-98.7%
Free cash flow-$132.8M-66.5%

Valuation

See full
Market cap$1.48B+111%
Enterprise value$1.29B+159%
P/S4.9×-32.1×

Profitability

See full
Gross margin96.1%-2.7pp
Operating margin-92.4%-45.5pp
Net margin-83%-40.9pp
FCF margin-686.5%-273pp

Returns & leverage

See full
Return on equity-26.1%-7.9pp
Debt / equity0.1×0.0×
Current ratio-1.0×

Where this comes from

Reported directly by Vir Biotechnology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Vir Biotechnology, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:20 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053549
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Selling, general and administrative30,19622,28353,53546,227
Restructuring, long-lived assets impairment and related charges, net(172)(182)
Total operating expenses165,479119,631297,740262,210
Income (loss) from operations73,467(118,417)(58,823)(257,964)
Other income:
Change in fair value of equity investments(1,723)(3,382)(1,893)3,000
Interest income8,96610,78516,15523,073
Other (expense) income, net(451)226(705)154

Item 1. Financial Statements (unaudited)

FAQ

What is Vir Biotechnology, Inc.'s operating income?
Vir Biotechnology, Inc. (VIR) reported operating income of $73.47M in Q2 2026.
How has Vir Biotechnology, Inc.'s operating income changed year-over-year?
Vir Biotechnology, Inc.'s operating income increased by 162.0% year-over-year, from -$118.42M to $73.47M.
What is the long-term trend for Vir Biotechnology, Inc.'s operating income?
Over 3 years (2021 to 2025), Vir Biotechnology, Inc.'s operating income has grown at a 4.4% compound annual growth rate (CAGR), from $420.75M to -$479.33M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Ask your AI about Vir Biotechnology, Inc.'s operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude